{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:21:03Z","timestamp":1793726463693,"version":"4.6.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["BFU2012-37087"],"award-info":[{"award-number":["BFU2012-37087"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud y Familias, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["RD12\/0019\/0020"],"award-info":[{"award-number":["RD12\/0019\/0020"]}],"id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015496","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red sobre Enfermedades Neurodegenerativas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.neuropharm.2014.05.021","type":"journal-article","created":{"date-parts":[[2014,5,27]],"date-time":"2014-05-27T15:52:46Z","timestamp":1401205966000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"C","title":["Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death"],"prefix":"10.1016","volume":"85","author":[{"given":"Ana","family":"Borrajo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"Rodriguez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Villar-Cheda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Labandeira-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2014.05.021_bib1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/cm.20472","article-title":"Rho-kinase\/ROCK: a key regulator of the cytoskeleton and cell polarity","volume":"67","author":"Amano","year":"2010","journal-title":"Cytoskelet. (Hob.)"},{"key":"10.1016\/j.neuropharm.2014.05.021_bib2","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1515\/hsz-2013-0181","article-title":"Rho-kinase: regulation, (dys)function, and inhibition","volume":"394","author":"Amin","year":"2013","journal-title":"Biol. Chem."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib3","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood.V93.5.1464","article-title":"NADPH oxidase: an update","volume":"93","author":"Babior","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.neuropharm.2014.05.021_bib4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coi.2003.12.001","article-title":"NADPH oxidase","volume":"16","author":"Babior","year":"2004","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib5","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/srep00809","article-title":"ROCK\/Cdc42-mediated microglial motility and gliapse formation lead to phagocytosis of degenerating dopaminergic neurons in\u00a0vivo","volume":"2","author":"Barcia","year":"2012","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/pmic.200900195","article-title":"Lysophosphatidic acid receptor activation affects the C13NJ microglia cell line proteome leading to alterations in glycolysis, motility, and cytoskeletal architecture","volume":"10","author":"Bernhart","year":"2010","journal-title":"Proteomics"},{"key":"10.1016\/j.neuropharm.2014.05.021_bib7","doi-asserted-by":"crossref","first-page":"10858","DOI":"10.1523\/JNEUROSCI.5010-12.2013","article-title":"NG2 regulates directional migration of oligodendrocyte precursor cells via Rho GTPases and polarity complex proteins","volume":"33","author":"Binam\u00e9","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1044-7431(02)00032-5","article-title":"Suppression of Rho-kinase activity promotes axonal growth on inhibitory CNS substrates","volume":"22","author":"Borisoff","year":"2003","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/glia.22595","article-title":"Microglial TNF-\u03b1 mediates enhancement of dopaminergic degeneration by brain angiotensin","volume":"62","author":"Borrajo","year":"2014","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2014.05.021_bib10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.tips.2005.12.002","article-title":"Targeting Rho and Rho-kinase in the treatment of cardiovascular disease","volume":"27","author":"Budzyn","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.expneurol.2012.01.011","article-title":"Axon degeneration in Parkinson's disease","volume":"246","author":"Burke","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/glia.20466","article-title":"ROCK inhibition with Y27632 activates astrocytes and increases their expression of neurite growth-inhibitory chondroitin sulfate proteoglycans","volume":"55","author":"Chan","year":"2007","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2014.05.021_bib13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1517\/13543784.2013.778242","article-title":"Fasudil and its analogs: a new powerful weapon in the long war against central nervous system disorders?","volume":"22","author":"Chen","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.neuropharm.2014.05.021_bib14","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/brain\/aws133","article-title":"Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease","volume":"135","author":"Chu","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2014.05.021_bib15","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1016\/j.neuropharm.2012.01.028","article-title":"Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease","volume":"62","author":"Collins","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2014.05.021_bib16","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1523\/JNEUROSCI.12-09-03392.1992","article-title":"A\u00a0novel N18TG2 x mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin","volume":"12","author":"Crawford","year":"1992","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib17","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/j.1471-4159.2010.06876.x","article-title":"Fasudil protects hippocampal neurons against hypoxia-reoxygenation injury by suppressing microglial inflammatory responses in mice","volume":"114","author":"Ding","year":"2010","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib18","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbi.2009.05.002","article-title":"Rho kinase inhibitor Fasudil induces neuroprotection and neurogenesis partially through astrocyte-derived G-CSF","volume":"23","author":"Ding","year":"2009","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.expneurol.2004.05.019","article-title":"Myosin II activity is required for severing-induced axon retraction in\u00a0vitro","volume":"189","author":"Gallo","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1289\/ehp.11031","article-title":"Flood PM, Block M, Hong JS: formyl-methionyl-leucyl-phenylalanine-induced dopaminergic neurotoxicity via microglial activation: a mediator between peripheral infection and neurodegeneration?","volume":"116","author":"Gao","year":"2008","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","article-title":"In\u00a0vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease","volume":"21","author":"Gerhard","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fnana.2010.00140","article-title":"Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease","volume":"4","author":"Gonz\u00e1lez-Hern\u00e1ndez","year":"2010","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib23","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1096\/fj.02-1014fje","article-title":"Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis","volume":"17","author":"Greenwood","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib24","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/01.RES.0000096650.91688.28","article-title":"Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in\u00a0vivo: effect on endothelial NAD(P)H oxidase system","volume":"93","author":"Higashi","year":"2003","journal-title":"Circ. Res."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib25","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1471-4159.2005.03443.x","article-title":"Role of Rho GTPase in astrocyte morphology and migratory response during in\u00a0vitro wound healing","volume":"95","author":"H\u00f6ltje","year":"2005","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1189\/jlb.0203054","article-title":"RhoA activation promotes transendothelial migration of monocytes via ROCK","volume":"75","author":"Honing","year":"2004","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1471-4159.2009.05999.x","article-title":"The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease","volume":"109","author":"Joglar","year":"2009","journal-title":"J.\u00a0Neurochem"},{"key":"10.1016\/j.neuropharm.2014.05.021_bib28","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1074\/jbc.273.5.2489","article-title":"p160 RhoA-binding kinase ROKalpha induces neurite retraction","volume":"273","author":"Katoh","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib29","first-page":"127","article-title":"Postnatal changes in Rho and Rho-related proteins in the mouse brain","volume":"47","author":"Komagome","year":"2000","journal-title":"Jpn. J. Vet. Res."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib30","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.2174\/138161207781368657","article-title":"Rho-ROCK inhibitors as emerging strategies to promote nerve regeneration","volume":"13","author":"Kubo","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1254\/jphs.08254FP","article-title":"Serofendic acid promotes stellation induced by cAMP and cGMP analogs in cultured cortical astrocytes","volume":"109","author":"Kume","year":"2009","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1476-5381.2011.01259.x","article-title":"The Rho kinase inhibitor Fasudil up-regulates astrocytic glutamate transport subsequent to actin remodelling in murine cultured astrocytes","volume":"163","author":"Lau","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib33","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1523\/JNEUROSCI.19-17-07537.1999","article-title":"Inactivation of Rho signaling pathway promotes CNS axon regeneration","volume":"19","author":"Lehmann","year":"1999","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.nurt.2010.05.014","article-title":"Microglial activation and chronic neurodegeneration","volume":"7","author":"Lull","year":"2010","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2014.05.021_bib35","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.cellsig.2013.05.023","article-title":"Involvement of small GTPase RhoA in the regulation of superoxide production in BV2 cells in response to fibrillar A\u03b2 peptides","volume":"25","author":"Moon","year":"2013","journal-title":"Cell Signal"},{"key":"10.1016\/j.neuropharm.2014.05.021_bib36","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd1719","article-title":"Rho kinase, a promising drug target for neurological disorders","volume":"4","author":"Mueller","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0014-5793(96)00811-3","article-title":"ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine\/threonine kinase in mice","volume":"392","author":"Nakagawa","year":"1996","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib38","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ceb.2008.01.002","article-title":"Applications for ROCK kinase inhibition","volume":"20","author":"Olson","year":"2008","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ana.20338","article-title":"Microglial activation and dopamine terminal loss in early Parkinson's disease","volume":"57","author":"Ouchi","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib40","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1242\/jcs.03004","article-title":"Synergistic effects of CoCl(2) and ROCK inhibition on mesenchymal stem cell differentiation into neuron-like cells","volume":"119","author":"Pacary","year":"2006","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib41","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/glia.22537","article-title":"Modulation of Rho-Rock signaling pathway protects oligodendrocytes against cytokine toxicity via PPAR-\u03b1-dependent mechanism","volume":"61","author":"Paintlia","year":"2013","journal-title":"Glia"},{"issue":"23\u201324","key":"10.1016\/j.neuropharm.2014.05.021_bib42","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.drudis.2013.09.010","article-title":"Advances in the development of Rho-associated protein kinase (ROCK) inhibitors","volume":"18","author":"Pan","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neuropharm.2014.05.021_bib43","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1042\/CS20050067","article-title":"NADPH oxidase and endothelial cell function","volume":"109","author":"Ray","year":"2005","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.neuropharm.2014.05.021_bib44","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1471-4159.2007.04699.x","article-title":"Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons","volume":"103","author":"Rodriguez-Pallares","year":"2007","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib45","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/j.1460-9568.2004.03621.x","article-title":"Angiotensin II increases differentiation of dopaminergic neurons from mesencephalic precursors via angiotensin type 2 receptors","volume":"20","author":"Rodriguez-Pallares","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib46","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.nbd.2008.03.003","article-title":"Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS","volume":"31","author":"Rodriguez-Pallares","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib47","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.nbd.2013.06.004","article-title":"Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease","volume":"58","author":"Rodriguez-Perez","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib48","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/1073858407303611","article-title":"ROCK and Rho: biochemistry and neuronal functions of Rho-associated protein kinases","volume":"13","author":"Schmandke","year":"2007","journal-title":"Neuroscientist"},{"key":"10.1016\/j.neuropharm.2014.05.021_bib49","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/glia.20815","article-title":"Lysophosphatidylcholine induces glial cell activation: role of rho kinase","volume":"57","author":"Sheikh","year":"2009","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2014.05.021_bib50","first-page":"61","article-title":"Advances in the mechanisms of Parkinson's disease","volume":"15","author":"Tolleson","year":"2013","journal-title":"Discov. Med."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib51","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1093\/brain\/aws254","article-title":"Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease","volume":"135","author":"T\u00f6nges","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2014.05.021_bib52","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.nbd.2012.04.010","article-title":"Involvement of microglial RhoA\/Rho-Kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors","volume":"47","author":"Villar-Cheda","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.neuropharm.2013.09.012","article-title":"Staurosporine induces dopaminergic neurite outgrowth through AMP-activated protein kinase\/mammalian target of rapamycin signaling pathway","volume":"77","author":"Wakita","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2014.05.021_bib54","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s10571-012-9845-z","article-title":"Rho-kinase inhibitor, fasudil, prevents neuronal apoptosis via the Akt activation and PTEN inactivation in the ischemic penumbra of rat brain","volume":"32","author":"Wu","year":"2012","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib55","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1471-4159.2011.07619.x","article-title":"Nogo-66 inhibits adhesion and migration of microglia via GTPase Rho pathway in\u00a0vitro","volume":"120","author":"Yan","year":"2012","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib56","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00401-007-0301-y","article-title":"Dexamethasone suppresses infiltration of RhoA+ cells into early lesions of rat traumatic brain injury","volume":"115","author":"Zhang","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib57","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1460-9568.2007.05404.x","article-title":"Phenylalanine activates the mitochondria-mediated apoptosis through the RhoA\/Rho-associated kinase pathway in cortical neurons","volume":"25","author":"Zhang","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.05.021_bib58","first-page":"119","article-title":"Rho\/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation","volume":"29","author":"Zohrabian","year":"2009","journal-title":"Anticancer Res."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814001889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814001889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:54:35Z","timestamp":1762214075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390814001889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":58,"alternative-id":["S0028390814001889"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.05.021","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}